This CPB has been revised to: (i) remove AIDS-related Kaposi sarcoma and leptomeningeal metastases from medically necessary indications for bevacizumab products (Avastin, Mvasi and Zirabev), as they are no longer recommended by NCCN for these indications, (ii) reformat the list of indications (e.g., grouped angiosarcoma and solitary fibrous tumor under soft tissue sarcoma; separated small bowel adenocarcinoma from colorectal cancer), (iii) update the nomenclature (e.g., changed kidney cancer to renal cell carcinoma), and (iv) update the dosing recommendations, background and references with additional information.